Shots:

• Ribometrix to get $20M up front including an equity investment in the company with $700M as development- regulatory and commercial milestones and royalties on sales on any product. Vertex to discover two programs in collaboration with Ribometrix and has an option to add the third program & to take exclusive WW license for the development and commercialization of molecules for that program
• The collaboration will combine Ribometrix’s discovery platform with Vertex’s clinical and regulatory capabilities for up to three therapeutic programs- including one ongoing discovery program from Ribometrix
• Ribometrix RNA-targeted therapeutics platform used for identifying and optimizing small molecule therapeutics- modulating the RNA function by targeting 3D RNA structure

Click here to­ read full press release/ article 

 Ref: Businesswire | Image: Vertex